RU2008110911A - Новые диазабициклические арильные производные и их медицинское применение - Google Patents
Новые диазабициклические арильные производные и их медицинское применение Download PDFInfo
- Publication number
- RU2008110911A RU2008110911A RU2008110911/04A RU2008110911A RU2008110911A RU 2008110911 A RU2008110911 A RU 2008110911A RU 2008110911/04 A RU2008110911/04 A RU 2008110911/04A RU 2008110911 A RU2008110911 A RU 2008110911A RU 2008110911 A RU2008110911 A RU 2008110911A
- Authority
- RU
- Russia
- Prior art keywords
- diazabicyclo
- nonane
- methyl
- pyridazin
- disorder
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 26
- 125000003118 aryl group Chemical group 0.000 claims abstract 18
- 201000010099 disease Diseases 0.000 claims abstract 13
- 208000035475 disorder Diseases 0.000 claims abstract 13
- 208000002193 Pain Diseases 0.000 claims abstract 5
- 102000005962 receptors Human genes 0.000 claims abstract 3
- 108020003175 receptors Proteins 0.000 claims abstract 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- -1 selenophenyl Chemical group 0.000 claims 16
- 125000000335 thiazolyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 3
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 102000034337 acetylcholine receptors Human genes 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004952 trihaloalkoxy group Chemical group 0.000 claims 2
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- FGOQONPFPVZWHX-UHFFFAOYSA-N 2-(4-chlorophenyl)-5-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)-1,3,4-thiadiazole Chemical compound CN1C(C2)CCCC1CN2C(S1)=NN=C1C1=CC=C(Cl)C=C1 FGOQONPFPVZWHX-UHFFFAOYSA-N 0.000 claims 1
- IDISALVIHFLVGH-UHFFFAOYSA-N 2-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)-5-phenyl-1,3,4-thiadiazole Chemical compound CN1C(C2)CCCC1CN2C(S1)=NN=C1C1=CC=CC=C1 IDISALVIHFLVGH-UHFFFAOYSA-N 0.000 claims 1
- XSQQPNAJQNHRDG-UHFFFAOYSA-N 3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1C(N2)CCCC2CN1C(N=N1)=CC=C1C1=CC=CC=C1 XSQQPNAJQNHRDG-UHFFFAOYSA-N 0.000 claims 1
- CYNAMJOAZBZKAX-UHFFFAOYSA-N 3-(6-phenylpyridazin-3-yl)-9-propan-2-yl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CC(C)N1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 CYNAMJOAZBZKAX-UHFFFAOYSA-N 0.000 claims 1
- VUWLIVJBMFYYTA-UHFFFAOYSA-N 3-[5-(1-benzofuran-2-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2OC(C3=CN=C(N=C3)N3CC4CCCC(C3)N4C)=CC2=C1 VUWLIVJBMFYYTA-UHFFFAOYSA-N 0.000 claims 1
- KEMGSELFJOETLU-UHFFFAOYSA-N 3-[5-(1h-indol-5-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2NC=CC2=CC(C2=CN=C(N=C2)N2CC3CCCC(C2)N3C)=C1 KEMGSELFJOETLU-UHFFFAOYSA-N 0.000 claims 1
- IKRUSLRJFTUYHB-UHFFFAOYSA-N 3-[5-(furan-2-yl)pyrimidin-2-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CO1 IKRUSLRJFTUYHB-UHFFFAOYSA-N 0.000 claims 1
- PUYRDTPXVOXEAZ-UHFFFAOYSA-N 3-[6-(1,3-benzodioxol-5-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2OCOC2=CC(C2=CC=C(N=N2)N2CC3CCCC(C2)N3C)=C1 PUYRDTPXVOXEAZ-UHFFFAOYSA-N 0.000 claims 1
- RMBARHWXTKPXTF-UHFFFAOYSA-N 3-[6-(1-benzofuran-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2OC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC2=C1 RMBARHWXTKPXTF-UHFFFAOYSA-N 0.000 claims 1
- VZYSWDFEPJQXTQ-UHFFFAOYSA-N 3-[6-(1-benzothiophen-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=C2SC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC2=C1 VZYSWDFEPJQXTQ-UHFFFAOYSA-N 0.000 claims 1
- OHRXMAVNLQVSHQ-UHFFFAOYSA-N 3-[6-(1h-indol-5-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)N2CC3CCCC(C2)N3C)=C1 OHRXMAVNLQVSHQ-UHFFFAOYSA-N 0.000 claims 1
- KKYYDKUWGOVCGA-UHFFFAOYSA-N 3-[6-(2,3-difluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1F KKYYDKUWGOVCGA-UHFFFAOYSA-N 0.000 claims 1
- XSGLPUSPWSLWGK-UHFFFAOYSA-N 3-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound O1CCOC2=CC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC=C21 XSGLPUSPWSLWGK-UHFFFAOYSA-N 0.000 claims 1
- YZFUYFPDFPMBDN-UHFFFAOYSA-N 3-[6-(2,3-dimethoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCCC(N3C)C2)=C1OC YZFUYFPDFPMBDN-UHFFFAOYSA-N 0.000 claims 1
- JXUDAISOBGNDHQ-UHFFFAOYSA-N 3-[6-(2-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1F JXUDAISOBGNDHQ-UHFFFAOYSA-N 0.000 claims 1
- XFXGDPHXKMDYST-UHFFFAOYSA-N 3-[6-(2-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 XFXGDPHXKMDYST-UHFFFAOYSA-N 0.000 claims 1
- OJZHWYNIPYNESI-UHFFFAOYSA-N 3-[6-(3,4-difluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C(F)=C1 OJZHWYNIPYNESI-UHFFFAOYSA-N 0.000 claims 1
- IOENKEPDMCPFPM-UHFFFAOYSA-N 3-[6-(3,4-dimethoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 IOENKEPDMCPFPM-UHFFFAOYSA-N 0.000 claims 1
- BIOCLXADHCTJJA-UHFFFAOYSA-N 3-[6-(3-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(Cl)=C1 BIOCLXADHCTJJA-UHFFFAOYSA-N 0.000 claims 1
- SHZQLOVONNAGPP-UHFFFAOYSA-N 3-[6-(3-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(F)=C1 SHZQLOVONNAGPP-UHFFFAOYSA-N 0.000 claims 1
- PYOUOBGQJNWMCN-UHFFFAOYSA-N 3-[6-(3-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound COC1=CC=CC(C=2N=NC(=CC=2)N2CC3CCCC(N3C)C2)=C1 PYOUOBGQJNWMCN-UHFFFAOYSA-N 0.000 claims 1
- ODYJYCSNOBKQJA-UHFFFAOYSA-N 3-[6-(4-chlorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)C=C1 ODYJYCSNOBKQJA-UHFFFAOYSA-N 0.000 claims 1
- IJEACVLCQBWHBA-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(F)C=C1 IJEACVLCQBWHBA-UHFFFAOYSA-N 0.000 claims 1
- UFPXNUQARADVFM-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N2CC3CCCC(N3C)C2)N=N1 UFPXNUQARADVFM-UHFFFAOYSA-N 0.000 claims 1
- KVDZBHUCZJIWTJ-UHFFFAOYSA-N 3-[6-(5-chlorothiophen-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(Cl)S1 KVDZBHUCZJIWTJ-UHFFFAOYSA-N 0.000 claims 1
- VZOUJCBJYJVQBQ-UHFFFAOYSA-N 3-[6-(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)pyridazin-3-yl]aniline Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(N)=C1 VZOUJCBJYJVQBQ-UHFFFAOYSA-N 0.000 claims 1
- QNFKEPYFXNMHBG-UHFFFAOYSA-N 3-[6-(furan-2-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CO1 QNFKEPYFXNMHBG-UHFFFAOYSA-N 0.000 claims 1
- IQHDJOUFKKIVFV-UHFFFAOYSA-N 3-[6-(furan-3-yl)pyridazin-3-yl]-9-methyl-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=COC=1 IQHDJOUFKKIVFV-UHFFFAOYSA-N 0.000 claims 1
- JFWZGJMWQOKJMP-UHFFFAOYSA-N 9-(2-methoxyethyl)-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound COCCN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 JFWZGJMWQOKJMP-UHFFFAOYSA-N 0.000 claims 1
- VEWDKPOTHCJJCR-UHFFFAOYSA-N 9-ethyl-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CCN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 VEWDKPOTHCJJCR-UHFFFAOYSA-N 0.000 claims 1
- JRHLBFCRXCSEPV-UHFFFAOYSA-N 9-methyl-3-(5-naphthalen-2-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=CC2=CC(C3=CN=C(N=C3)N3CC4CCCC(C3)N4C)=CC=C21 JRHLBFCRXCSEPV-UHFFFAOYSA-N 0.000 claims 1
- GAJASBATEWQDPZ-UHFFFAOYSA-N 9-methyl-3-(5-phenylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CC=C1 GAJASBATEWQDPZ-UHFFFAOYSA-N 0.000 claims 1
- UTXORWNBSQBQHP-UHFFFAOYSA-N 9-methyl-3-(5-thiophen-2-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C1=CC=CS1 UTXORWNBSQBQHP-UHFFFAOYSA-N 0.000 claims 1
- GPYXLWLDRHEQQL-UHFFFAOYSA-N 9-methyl-3-(5-thiophen-3-ylpyrimidin-2-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=C1)=NC=C1C=1C=CSC=1 GPYXLWLDRHEQQL-UHFFFAOYSA-N 0.000 claims 1
- STSJVLWHJVKQCN-UHFFFAOYSA-N 9-methyl-3-(6-naphthalen-2-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound C1=CC=CC2=CC(C3=CC=C(N=N3)N3CC4CCCC(C3)N4C)=CC=C21 STSJVLWHJVKQCN-UHFFFAOYSA-N 0.000 claims 1
- YBVCONMKJCCKQC-UHFFFAOYSA-N 9-methyl-3-(6-phenylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC=C1 YBVCONMKJCCKQC-UHFFFAOYSA-N 0.000 claims 1
- KYCGHQNQAAJCII-UHFFFAOYSA-N 9-methyl-3-(6-thiophen-2-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CS1 KYCGHQNQAAJCII-UHFFFAOYSA-N 0.000 claims 1
- FGMNOBQFMPYCPT-UHFFFAOYSA-N 9-methyl-3-(6-thiophen-3-ylpyridazin-3-yl)-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C=1C=CSC=1 FGMNOBQFMPYCPT-UHFFFAOYSA-N 0.000 claims 1
- NCKJDGFAVZUBPM-UHFFFAOYSA-N 9-methyl-3-[6-(1h-pyrrol-2-yl)pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CN1 NCKJDGFAVZUBPM-UHFFFAOYSA-N 0.000 claims 1
- GQYYKRWORSNPBS-UHFFFAOYSA-N 9-methyl-3-[6-[3-(trifluoromethyl)phenyl]pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 GQYYKRWORSNPBS-UHFFFAOYSA-N 0.000 claims 1
- ZSLOGSYNSRFQFQ-UHFFFAOYSA-N 9-methyl-3-[6-[4-(trifluoromethyl)phenyl]pyridazin-3-yl]-3,9-diazabicyclo[3.3.1]nonane Chemical compound CN1C(C2)CCCC1CN2C(N=N1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 ZSLOGSYNSRFQFQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020651 Hyperkinesia Diseases 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028403 Mutism Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000001713 cholinergic effect Effects 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000016160 smooth muscle contraction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501724 | 2005-12-06 | ||
| DKPA200501724 | 2005-12-06 | ||
| US74822205P | 2005-12-08 | 2005-12-08 | |
| US60/748,222 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008110911A true RU2008110911A (ru) | 2010-01-20 |
Family
ID=40114330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008110911/04A RU2008110911A (ru) | 2005-12-06 | 2006-12-05 | Новые диазабициклические арильные производные и их медицинское применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8173658B2 (https=) |
| EP (2) | EP1963323B1 (https=) |
| JP (1) | JP2009518357A (https=) |
| KR (1) | KR20080079250A (https=) |
| CN (1) | CN101305004B (https=) |
| AT (1) | ATE473978T1 (https=) |
| AU (1) | AU2006323986A1 (https=) |
| BR (1) | BRPI0617772A2 (https=) |
| CA (1) | CA2632642A1 (https=) |
| DE (1) | DE602006015523D1 (https=) |
| DK (1) | DK1963323T3 (https=) |
| NZ (1) | NZ567048A (https=) |
| RU (1) | RU2008110911A (https=) |
| WO (1) | WO2007065892A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007213670A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AU2007213671A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists |
| CN101379063A (zh) | 2006-02-10 | 2009-03-04 | 神经研究公司 | 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途 |
| JP2009526777A (ja) | 2006-02-14 | 2009-07-23 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体作用薬としての３，９−ジアザビシクロ（３．３．１）ノナ−３−イル−アリールメタノン誘導体 |
| EP2029607A1 (en) | 2006-05-23 | 2009-03-04 | NeuroSearch A/S | Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| US20110142758A1 (en) * | 2008-06-10 | 2011-06-16 | Neurosearch A/S | Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| CN103180321A (zh) | 2010-09-23 | 2013-06-26 | Abbvie公司 | 氮杂金刚烷衍生物的一水合物 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| CN108658762B (zh) * | 2018-06-12 | 2021-03-02 | 浙江凯普化工有限公司 | 一种脂环邻二酯的合成方法 |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3293251A (en) * | 1966-12-20 | Rearrangement process for j,b-diaza- bicyclo-(j,z,i)-octane derivatives | ||
| US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
| NZ500645A (en) | 1997-05-30 | 2001-06-29 | Neurosearch As | 9-Azabicyclo[3.3.1]non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACh receptors |
| CA2289574C (en) | 1997-05-30 | 2007-04-24 | Neurosearch A/S | 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors |
| FR2786770B1 (fr) | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| TR200102162T2 (tr) | 1999-01-29 | 2001-12-21 | Abbott Laboratories | Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler. |
| US7265115B2 (en) * | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| EP1177196B1 (en) | 1999-05-04 | 2004-03-10 | Neurosearch A/S | Heteroaryl diazabicycloalkanes, their preparation and use |
| JP2003534344A (ja) | 2000-05-25 | 2003-11-18 | ターガセプト，インコーポレイテッド | ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン |
| FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| FR2809731B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
| ATE287888T1 (de) * | 2000-07-04 | 2005-02-15 | Neurosearch As | Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung |
| WO2002096911A1 (en) * | 2001-06-01 | 2002-12-05 | Neurosearch A/S | Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| FR2832713B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| FR2832712B1 (fr) | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique |
| DE60310548T2 (de) | 2002-05-07 | 2007-05-10 | Neurosearch A/S | Diazabicyclische biarylderivate |
| DK1562945T3 (da) | 2002-11-11 | 2007-03-05 | Neurosearch As | Hidtil ukendte diazebicykliske biarylderivater |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| BRPI0415683A (pt) * | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
| EP1805183B1 (en) | 2004-10-20 | 2010-12-29 | NeuroSearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| CA2588961A1 (en) | 2004-11-30 | 2006-06-08 | Neurosearch A/S | Novel diazabicyclic aryl derivatives as cholinergy ligands |
| WO2006087306A2 (en) | 2005-02-16 | 2006-08-24 | Neurosearch A/S | Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors |
| JP5052952B2 (ja) * | 2007-05-07 | 2012-10-17 | 東芝機械株式会社 | マイクロレンズ転写成形用ロールの製造方法および製造装置 |
| AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
-
2006
- 2006-12-05 CA CA002632642A patent/CA2632642A1/en not_active Abandoned
- 2006-12-05 AT AT06830366T patent/ATE473978T1/de active
- 2006-12-05 EP EP06830366A patent/EP1963323B1/en not_active Not-in-force
- 2006-12-05 KR KR1020087013706A patent/KR20080079250A/ko not_active Withdrawn
- 2006-12-05 DK DK06830366.8T patent/DK1963323T3/da active
- 2006-12-05 BR BRPI0617772-7A patent/BRPI0617772A2/pt not_active IP Right Cessation
- 2006-12-05 US US12/093,655 patent/US8173658B2/en not_active Expired - Fee Related
- 2006-12-05 DE DE602006015523T patent/DE602006015523D1/de active Active
- 2006-12-05 WO PCT/EP2006/069316 patent/WO2007065892A1/en not_active Ceased
- 2006-12-05 RU RU2008110911/04A patent/RU2008110911A/ru unknown
- 2006-12-05 JP JP2008543818A patent/JP2009518357A/ja not_active Abandoned
- 2006-12-05 NZ NZ567048A patent/NZ567048A/en not_active IP Right Cessation
- 2006-12-05 CN CN2006800416608A patent/CN101305004B/zh not_active Expired - Fee Related
- 2006-12-05 EP EP10164285A patent/EP2246352A1/en not_active Withdrawn
- 2006-12-05 AU AU2006323986A patent/AU2006323986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0617772A2 (pt) | 2011-08-09 |
| CN101305004B (zh) | 2011-11-16 |
| EP1963323A1 (en) | 2008-09-03 |
| JP2009518357A (ja) | 2009-05-07 |
| EP1963323B1 (en) | 2010-07-14 |
| KR20080079250A (ko) | 2008-08-29 |
| US8173658B2 (en) | 2012-05-08 |
| WO2007065892A1 (en) | 2007-06-14 |
| US20080280912A1 (en) | 2008-11-13 |
| DE602006015523D1 (de) | 2010-08-26 |
| CA2632642A1 (en) | 2007-06-14 |
| NZ567048A (en) | 2010-12-24 |
| EP2246352A1 (en) | 2010-11-03 |
| CN101305004A (zh) | 2008-11-12 |
| ATE473978T1 (de) | 2010-07-15 |
| DK1963323T3 (da) | 2010-10-25 |
| AU2006323986A1 (en) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008110911A (ru) | Новые диазабициклические арильные производные и их медицинское применение | |
| CA2389553A1 (en) | Heteroaryl-diazabicycloalkanes | |
| RU2007139255A (ru) | Новые оксадиазольные производные и их медицинское применение | |
| JP2009538866A5 (https=) | ||
| US20100029685A1 (en) | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| CN100432075C (zh) | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 | |
| JP2004538268A5 (https=) | ||
| JP2009518357A5 (https=) | ||
| JP2009538867A5 (https=) | ||
| WO2010060854A1 (en) | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | |
| JP2012526736A5 (https=) | ||
| CN101035792B (zh) | 新颖的二氮杂双环芳基衍生物和它们的医药用途 | |
| JP2005524713A5 (https=) | ||
| JP2008517032A5 (https=) | ||
| JP2008530171A5 (https=) | ||
| JP2006508109A (ja) | １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用 | |
| KR20060125885A (ko) | 콜린 수용체 조절제로서의 디아자바이사이클릭 아릴 유도체 | |
| JP2006503062A5 (https=) | ||
| JP2008530172A5 (https=) | ||
| JP2008530172A (ja) | ジアザ二環系アリール誘導体及びそれらのニコチン様アセチルコリン受容体におけるコリン作動性リガンドとしての使用 | |
| JP2008530171A (ja) | 新規なジアザ二環系アリール誘導体及びそれらの医療上の使用 | |
| JP2009537599A (ja) | 新規８，１０−ジアザ−ビシクロ［４．３．１］デカン誘導体及びそれらの医学的使用 | |
| RU2007106970A (ru) | Новые хромен-2-оновые производные и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов | |
| JP2007515479A5 (https=) |